NUUU — Rejuvel Bio-Sciences Share Price
Last trade - 00:00- $0.00m
- $0.36m
- $0.09m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -672.65% | ||
Financial Summary
| Year End 31st Dec | Unit | 2010 | 2011 | 2012 | 2013 | 2014 | 2015E | 2016E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 0 | 0.01 | 0.05 | 0.09 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Rejuvel Bio-Sciences, Inc., formerly Technology Applications International Corporation, is engaged in developing market entry technology products and services into early and mainstream technology products and services. The Company, through its subsidiaries, is focused on developing and manufacturing a line of technologically advanced skin care products and providing environmental management solutions that use electron particle accelerator technology. The Company offers REJUVEL 3D, which is ageless infinity microgravity cell renewal cream. REJUVEL 3D is a three-dimensional (3D) skin renewal system using National Aeronautics and Space Administration (NASA) technology. REJUVEL 3D has been formulated to address the skin care needs of both men and women of all skin types. The Company's subsidiaries include Rejuvel Int'l, Inc. and NueEarth, Inc.
Directors
- Last Annual
- December 31st, 2014
- Last Interim
- September 30th, 2015
- Incorporated
- October 14th, 2009
- Public Since
- February 13th, 2014
- No. of Employees
- 1
- Sector
- Specialty Retailers
- Industry
- Consumer Cyclicals
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 51,841,723
- Address
- 1173 Brook Drive East, DUNEDIN, 34698
- Web
- http://rejuvel.com/
- Phone
- +1 7867870402
- Auditors
- Sadler, Gibb & Associates, LLC
Similar to NUUU
Arion
Pink Sheets on Nasdaq
Avolta AG
Pink Sheets on Nasdaq
bebe stores
Pink Sheets on Nasdaq
Better for You Wellness
Pink Sheets on Nasdaq
BioForce Nanosciences Holdings
Pink Sheets on Nasdaq
FAQ
As of Today at 19:18 UTC, shares in Rejuvel Bio-Sciences are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Rejuvel Bio-Sciences last closed at $0.00 and the price had moved by over the past 365 days. In terms of relative price strength the Rejuvel Bio-Sciences share price has underperformed the S&P500 Index by -11.77% over the past year.
There is no consensus recommendation for this security.
Rejuvel Bio-Sciences does not currently pay a dividend.
Rejuvel Bio-Sciences does not currently pay a dividend.
Rejuvel Bio-Sciences does not currently pay a dividend.
To buy shares in Rejuvel Bio-Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Rejuvel Bio-Sciences had a market capitalisation of $0.00m.
Here are the trading details for Rejuvel Bio-Sciences:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: NUUU
Based on an overall assessment of its quality, value and momentum Rejuvel Bio-Sciences is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rejuvel Bio-Sciences. Over the past six months, its share price has underperformed the S&P500 Index by -13.79%.
As of the last closing price of $0.00, shares in Rejuvel Bio-Sciences were trading -99.09% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Rejuvel Bio-Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Rejuvel Bio-Sciences' management team is headed by:
- Charles Scimeca - PRE
- Joseph Pavlik - CEO
- Matthew Cohen - CFO